Ankara Numune Eğitim ve Araştırma Hastanesinde Hastane Enfeksiyonu Etkeni Olarak İzole Edilen Candida Suşlarının Dağılımı 2010-2015
Amaç: Son yıllarda nozokomiyal Candida enfeksiyonlarının epidemiyolojisinde ve tedavisinde kullanılan antifungallerle ilgili önemli değişiklikler ortaya çıkmıştır. Nozokomiyal Candida enfeksiyonlarının en sık etkeni Candida albicans olmakla birlikte, son zamanlarda albicans dışı Candida türlerinin de sıklığı artmaktadır. Bu çalışmada nozokomiyal Candida enfeksiyonlarından izole edilen Candida türlerinin dağılımı değerlendirilerek hastanemiz ve ülkemiz epidemiyolojik verilerine katkı sağlanması amaçlanmıştır. Yöntem: Çalışmada Ocak 2010-Aralık 2015 tarihleri arasında Ankara Numune Eğitim ve Araştırma Hastanesi yoğun bakım ve klinik sevislerinde yatarak tedavi gören hastalarda gelişen 3840 nozokomiyal enfeksiyondan izole edilen etkenler değerlendirilmiştir. Çeşitli klinik örneklerden izole edilen Candida suşları Hastane Enfeksiyon Kontrol Komitesi tarafından Hastalık Kontrol ve Önleme Merkezi CDC kriterlerine göre nozokomiyal enfeksiyon etkeni olarak kabul edilmiştir. Nozokomiyal enfeksiyon etkeni olarak tespit edilen 350 Candida suşunun dağılımı incelenmiştir.Bulgular: İzlenen dönem içinde Ankara Numune Eğitim ve Araştırma Hastanesi yoğun bakım ünitelerinde 2559, klinik ünitelerinde 1281 nozokomiyal enfeksiyon tespit edilmiştir.Nozokomiyal enfeksiyon etkenleri içinde Candida türleri, yoğun bakım ünitelerinde %11,2, klinik ünitelerde %3,7 oranında olarak saptanmıştır. Candida albicans %39,7 , nozokomiyal kandida enfeksiyonlarına neden olan türler arasında en sık görülen etken olarak tespit edilmiştir. Albicans dışı kandida türleri arasında ise en sık görülen etkenin C. parapsilosis %20,9 olduğu saptanmış, bunu C. glabrata %17,4 ve C. tropicalis %15,1 izlemiştir. En sık karşılaşılan nozokomiyal kandida enfeksiyonu, üriner sistem enfeksiyonu olarak tespit edilmiştir.Sonuç: Nozokomiyal Candida enfeksiyonlarının epidemiyolojisi yıllara göre ve merkezlere göre değişebilmektedir. Nozokomiyal Candida enfeksiyonlarının uygun yönetilebilmesi için hastanelerde düzenli aralıklarla epidemiyolojik çalışmaların yapılması gereklidir
Distribution of Candida species isolated from Nosocomial infections of Ankara Numune Training and Research Hospital 2010-2015
Objective: In the recent years, the epidemiology of nosocomial Candida infections and antifungals used in the treatment have changed significantly. Although Candida albicans is the most frequently identified species, but incidence of non-albicans Candida species are increased lately. In this study, it is aimed to contribute to the epidemiological database of our hospital and country by evaluating the distribution of Candida species isolated from nosocomial Candida infections. Methods: It was evaluated that agents isolated from 3840 nosocomial infections that detected in patients hospitalized in intensive care units and clinical departments of Ankara Research and Training Hospital during January 2010 and December 2015. Candida species isolated from various clinical specimens were evaluated by Infection Control Committee according to the “Centers for Disease Control and Prevention CDC ” criteria. Distrubition of 350 Candida species isolated from nosocomial infections were investigated. Results: During the study period, the number of nosocomial infections determined among the patients hospitalized at the intensive care units and clinical departments of Ankara Research and Training Hospital were 2559 and 1281 respectively. The rate of Candida species detected from nosocomial infections in intensive care units and clinical departments were 11.2%, 3.7% respectively. The most common Candida species identified as an agent of nosocomial Candida infections was Candida albicans 39.7% . Among the non-albicans Candida group, C. parapsilosis 20.9% was the most common agent followed by C. glabrata 17.4% and C. tropicalis 15.1% . The most common nosocomial Candida infections were detected as Urinary tract infections. Conclusion: Epidemiology of nosocomial Candida infections can change to years and by hospital. Epidemiological studies should be performed at regular intervals in all hospitals in order to appropriate control of nosocomial Candida infections.
___
- 1. Eggimann P, Que YA, Revelly JP, Pagani JL. Preventing
invasive candida infections. Where could we do better?
J Hosp Infect, 2015; 89 (4): 302-8.
- 2. Kauffman CA. Fungal Infections. Proc Am Thorac
Soc, 2006; 3 (1): 35-40.
- 3. Khan ZU, Chandy R, Metwali KE. Candida albicans
strain carriage in patients and nursing staff of an
intensive care unit: a study of morphotypes and
resistotypes. Mycoses, 2003; 46 (11-12): 479-86.
- 4. Tiraboschi IN, Bennett JE, Kauffman CA, Rex JH,
Girmenia C, Sobel JD et al. Deep Candida infections
in theneutropenic and on-neutropenic host: an
ISHAM symposium. Med Mycol, 2000; 38(1): 199-
204.
- 5. Brown GD, Denning DW, Gow NA, Levitz SM,
Netea MGWhite TC. Hidden killers: human fungal
infections. Science translational medicine, 2012;
4(165): 165rv13.
- 6. Vincent JL, Rello J, Marshall J, Silva E, Anzueto
A, Martin CD, et al. International study of the
prevalence and outcomes of infection in intensive
care units. JAMA, 2009; 302 (23): 2323-29.
- 7. Pfaller MA, Castanheira M. Nosocomial Candidiasis:
Antifungal Stewardship and the Importance of
Rapid Diagnosis . Medical Mycology, 2016; 54(1):
1-22.
- 8. Horan TC, Andrus M, Dudeck MA. CDC/NHSN
surveillance definition of healthcare-associated
infection and criteria for specific types of infections
in the acute care setting. Am J Infect Control,
2008; 36(5): 309-32.
- 9. Fridkin SK, Jarvis WR. Epidemiology of nosocomial
fungal infections. Clin Microbiol Rev, 1996; 9(4):
499-511.
- 10. Horasan EŞ, Ersöz G, Göksu M, Otag F, Kurt AO,
Karaçorlu S.ve ark. Increase in Candida parapsilosis
fungemia in critical care units: a 6-years study.
Mycopathologia, 2010; 170(4): 263-8.
- 11. Otağ F, Aslan G, Şen S, Özturhan H, Emekdaş G.
2003-2005 süresinde klinik örneklerden izole edilen
maya türlerinin değerlendirilmesi. Infeks Derg,
2005; 19:435-43.
- 12. Pfaller MA, Castanheira M, Messer AS, Moet GJ,
Jones RN. Variation in Candida spp. distribution
and antifungal resistance rates among bloodstream
infection isolates by patient age: report from the
SENTRY Antimicrobial Surveillance Program (2008-
2009). Diagn Microbiol Infect Dis, 2010; 68(3): 278-
83.
- 13. Kibbler CC, Seaton S, Barnes RA, Gransden WR,
Holliman RE, Johnson EM. et al. Management and
outcome of bloodstream infections due to Candida
species in England and Wales. J Hosp Infect, 2003;
54(1): 18-24.
- 14. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White
J, Nicolas-Chanoin MH, et al. The prevalence
of nosocomial infection in intensive care units
in Europe. Results of the European Prevalence
of Infection in Intensive Care (EPIC) Study. EPIC
International Advisory Committee. JAMA, 1995;
274(8): 639-44
- 15. Bougnoux ME, Kac G, Aegerter P, d’Enfert C,
Fagon JY; CandiRea Study Group. Candidemia and
candiduria in critically ill patients admitted to
intensive care units in France: incidence, molecular
diversity, management and outcome. Intensive
Care Med, 2008; 34(2): 292-9
- 16. Comert F, Kulah C, Aktas E, Eroglu O, Ozlu N.
Identification of Candida species isolated from
patients in intensive care unit and in vitro
susceptibility to fluconazole for a 3-year period.
Mycoses, 2006; 50(1): 52-7
- 17. Erdem F, Tuncer Ertem G, Oral B, Karakoç
E, Demiröz AP, Tülek N. Epidemiological and
microbiological evaluation of nosocomial infections
caused by Candida species. Mikrobiyol Bul, 2012;
46(4):637-48.
- 18. Pfaller MA, Diekema DJ, Newell VA, Ellis D, Tullio
V, Rodloff A. Results from the ARTEMIS DISK Global
Antifungal Surveillance Study, 1997 to 2007: a 10.5-
Year Analysis of Susceptibilities of Candida Species
to Fluconazole and Voriconazole as Determined by
CLSI Standardized Disk Diffusion. J Clin Microbiol,
2010; 48(4): 1366–1377.
- 19. Phaller MA, Jones RN, Doern GV, Sader HS, Messer
SA. International surveillance of bloodstream
infections due to Candida species: frequency
of occurrence and antifungal susceptibilities of
isolates collected in1997 in the United States,
Canada and South America for the SENTRY program.
J Clin Microbiol, 1998; 36 (7): 1886-9.
- 20. St-Germain G, Laverdie M, Pelletier R, A.-
M. Bourgault, M. Libman, C. Lemieux, et al.
Prevalence and antifungal susceptibility of 442
Candida isolatesfrom blood and other normally
sterile sites: results of a 2-year (1996 to 1998)
multicenter surveillance study in Quebec, Canada.
J Clin Microbiol, 2001; 39(3): 949-53.
- 21. Acar A, Oncul O, Kucukardalı Y, Ozyurt M,
Haznedaroğlu T, Cavuşlu Ş. Yoğun bakım unitelerinde
saptanan Candida enfeksiyonlarının epidemiyolojik
özellikleri ve mortaliteye etki eden risk faktorleri.
Mikrobiyol Bul, 2008; 42(3): 451-61.
- 22. Snydman DR. Shifting patterns in the epidemiology
of nosocomial Candida infections. Chest, 2003; 123
(5 Suppl): 500-3.
- 23. Guinea J. Global trends in the distribution of
Candida species causing candidemia. Clin Microbiol
Infect, 2014;(20): 5-10.
- 24. Pfaller MA, Diekema DJ. Epidemiology of invasive
candidiasis: a persistent public health problem.
Clin Microbiol Rev, 2007; 20(1): 133–163.
- 25. Yapar N, Pullukcu H, Avkan-Oguz V, Sayin-Kutlu S,
Ertugrul B, Sacar S, et al. Evaluation of species
distribution and risk factors of candidemia: a
multicenter case-control study. Med Mycol, 2011;
49(1): 26-31.
- 26. Bakir M, Cerikcioglu N, Barton R, Yagci A.
Epidemiology of candidemia in a Turkish tertiary
care hospital. APMIS, 2006; 114(9): 601-10.
- 27. Adiloğlu AK, Şirin MC, Cicioglu-Arıdoğan B, Can R,
Demirci M. Çeşitli klinik örneklerden izole edilen
Candida kökenlerinin identifikasyonu ve antifungal
duyarlılıklarının araştırılması. ADÜ Tıp Fak Derg,
2004; 5(3):33-6.